Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
QuintilesIMS
McKesson
Chinese Patent Office
Express Scripts
Moodys
Julphar
Harvard Business School
Colorcon
Medtronic

Generated: January 16, 2018

DrugPatentWatch Database Preview

Deutetrabenazine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for deutetrabenazine and what is the scope of deutetrabenazine freedom to operate?

Deutetrabenazine
is the generic ingredient in one branded drug marketed by Teva Branded Pharm and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Deutetrabenazine has twenty-nine patent family members in eleven countries.

One supplier is listed for this compound.
Summary for deutetrabenazine
International Patents:29
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 6
Clinical Trials: 6
Patent Applications: 8
Drug Prices:see low prices
DailyMed Link:deutetrabenazine at DailyMed

US Patents and Regulatory Information for deutetrabenazine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-003 Apr 3, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-002 Apr 3, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-003 Apr 3, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-001 Apr 3, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Branded Pharm AUSTEDO deutetrabenazine TABLET;ORAL 208082-003 Apr 3, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for deutetrabenazine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,346,800 Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for deutetrabenazine

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Covington
AstraZeneca
US Army
QuintilesIMS
US Department of Justice
UBS
Cipla
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot